Pure Global

Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia - Trial NCT06380777

Access comprehensive clinical trial information for NCT06380777 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking Union Medical College Hospital and is currently Recruiting. The study focuses on Sarcopenia. Target enrollment is 10000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06380777
Recruiting
Trial Details
ClinicalTrials.gov โ€ข NCT06380777
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia
Establishment and Application of a Digital Diagnosis and Treatment System for Sarcopenia

Study Focus

Sarcopenia

Observational

Sponsor & Location

Peking Union Medical College Hospital

Beijing, China

Timeline & Enrollment

N/A

Sep 01, 2023

Dec 31, 2028

10000 participants

Primary Outcome

Appendicular skeletal muscle mass index

Summary

The goal of this observational study is to establish a digital diagnosis and treatment system
 for sarcopenia, integrating research outcomes into a unified approach encompassing a digital
 vaccine (early warning screening model), digital drug (intervention model associated with
 pathogenesis), and digital rehabilitation (preventive system combining early warning and
 treatment). This aims to create a digital visual tertiary prevention network for sarcopenia.
 
 Research aims:
 
 Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological
 survey.
 
 Establish a specialized cohort for sarcopenia through a longitudinal investigation,
 implementing the digital drug and digital rehabilitation interventions.
 
 Participants will:
 
 Engage in screening and assessment based on inclusion and exclusion criteria.
 
 Be monitored longitudinally, with tailored interventions for those with muscle atrophy and
 regular follow-ups for at-risk individuals.
 
 Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints
 such as fracture rates, weakness classification, and quality of life.

ICD-10 Classifications

Kaposi sarcoma
Hernia
Taeniasis
Taenia saginata taeniasis
Diaphragmatic hernia

Data Source

ClinicalTrials.gov

NCT06380777

Non-Device Trial